‍‍Member of Chinese academy of sciences, Professor and doctoral supervisor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Professor and Director of academic committee of Shanghai University of Traditional Chinese Medicine.

‍‍Currently, he is Deputy Chief Specialist of the National Science and Technology Major Project- “Innovative Drug Research & Development”，Deputy Chairman of China Pharmacopoeia Committee, Chief Supervisor of China Pharmaceutical Association and Vice President of China Society of Traditional Chinese Medicine.

‍‍He was President of Shanghai Association for Science and Technology（2011-2018）, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences（1996-2004）, President of Shanghai University of Traditional Chinese Medicine（2005-2014）, President of Chinese Society of Integrative Medicine（2008-2015），and Vice President of Chinese Pharmaceutical Association (2007-2016).‍‍‍‍

‍‍Over the years, he has devoted himself to the study of structure-activity relationship and new drug discovery，and is one of the leading scientists in this field in China. He has been the chief scientist of “project 973” for two times, and has undertaken a number of National, Chinese Academy of Sciences and local major scientific research projects. He has also actively participated in the National, Chinese Academy of Sciences and Shanghai municipal biomedical science and technology development strategy research, and implementation of major projects. All these have promoted China's innovative drug research and development and construction of technology system for drug innovation, and made contributions to the modernization and internationalization of Traditional Chinese Medicine.‍‍‍‍

‍‍Prof. Fan Xianqun is currently Deputy Secretary of the CPC of Shanghai Jiao Tong University, Secretary of the CPC of Shanghai Jiao Tong University School of Medicine.

‍‍Prof. Fan was awarded as Chang Jiang Scholarship by Ministry of Education of China, Expert with Outstanding Contributions by the Ministry of Human Resources and Social Security of China. He also was awarded the Fellowship of Royal College of Ophthalmologists (UK) and Fellowship Ad Hominem of Royal College of Surgeons of Edinburgh (UK).‍‍

‍‍Prof. Fan has been devoting his efforts to investigate orbital diseases and ocular tumors. Prof. Fan was in charge of 13 national research grants, which includes National 863 program, project of National Natural Science Foundation and the Ministry of Science and Technology of China. He has published 150 peer-reviewed SCI papers as the first author or corresponding author.He has received successively 13 awards, such as Second Prize of National Science and Technology Progress Awards.‍‍

‍‍Prof. Fan was named the Excellent Talent by the Ministry of Health of China, National Excellent Scientific and Technical Talent by the Ministry of Science and Technology of China, the Shanghai Leading Talent by Shanghai Municipal Governmen, the Wu Jieping-Paul Janssen Medical & Pharmaceutical Award.‍‍‍‍

Dr. Jia is an academician of the Chinese Academy of Engineering, member of the Chinese Academy of Medical Sciences, director of the Shanghai Diabetes Institute, director of the National office for primary diabetes care, and chief editor of the Chinese Journal of Internal Medicine. She was the chairman of Chinese Diabetes Society(2016-2019). Jia Weiping has long been committed to precise diagnosis and treatment, early warning screening, pathogenesis research and prevention engineering management of diabetes. She has published over 300 original articles as first and/or corresponding authors in journals, including BMJ, Lancet Diabetes Endocrinol, Cell Metab, Nat Biotechnol, Sci Transl Med, Diabetes, Diabetes Care, J Hepatol, etc. She has been awarded the national science and technology progress prizes, the provincial science and technology progress prizes, the Xiaoren Pan distinguished research prize for epidemiology of diabetes in Asia, the Ho Leung Ho Lee Foundation science and technology prize, and the Tan Jiazhen life science prize, etc.

‍‍Zihe Rao, Professor of Tsinghua University, Former President of Nankai University and Former Director-General of the Institute of Biophysics, CAS.

‍‍Prof Rao is a structural biologist whose research focus is on the study of pathogenic infectious agents. His work has provided insights into viral infection, replication and assembly, and into energy and metabolite transport, drug resistance and cell wall synthesis in Mycobacteria tuberculosis. His most recent work on picornaviruses, herpesvirus, Mycobacteria tuberculosis provided much-needed structural data for the design and development of new anti-viral and anti-TB drugs. To date, Prof Rao has published 360 peer-reviewed papers in international scientific journals with over 15,000 citations. ‍‍‍‍

‍‍‍‍‍‍‍‍‍‍Dr. Xiaodong Wang is currently the Director and Investigator of National Institute of Biological Sciences, Beijing. He received his B.S. degree from Beijing Normal University and his Ph.D. degree of Biochemistry from University of Texas Southwestern Medical Center at Dallas. After his postdoctoral training at the Department of Molecular Genetics at the same school, he started his independent research career at Emory University in Atlanta. He returned to UT-Southwestern in 1996 as a faculty member at the Department of Biochemistry and held the position of George MacGregor Distinguished Professor until he returned to Beijing to take his current position in 2010. He was also an Investigator of Howard Hughes Medical Institute from 1997 to 2010. Dr. Xiaodong Wang’s research centers on the biochemical understanding of programmed cell death in mammalian cells.  Their laboratory is responsible for the discovery of the role of cytochrome c in apoptosis that established the signaling function of mitochondria. Their more recent work identified RIP3 kinase and its substrate MLKL as the core components of a pathway controlling and executing programmed necrosis. For his research achievements, Dr. Xiaodong Wang was elected to be a member of National Academy of Sciences, USA; Foreign-associate member of Chinese Academy of Sciences and European Molecular Biology Organization.‍‍

 ‍‍‍‍‍‍‍‍

‍‍Following medical practices in Shanghai, Dr. Ming-Wei Wang obtained his Ph.D. from University of Cambridge in 1989. He worked for a couple of US-based biotech companies a year later and served as a consultant to Merck and UNDP on China-related projects in the mid-1990’s. Thereafter, he was engaged in various entrepreneur activities. Dr. Wang joined the faculty of Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2001 and became Director of the National Center for Drug Screening in 2003. In 2004, he was named by Shanghai Pudong New District Government as a Senior Business Advisor. He founded the Chinese National Compound Library and has been its first director since 2012. Dr. Wang was appointed as Dean, School of Pharmacy, Fudan University in 2015. He is also an editorial board member of Trends in Pharmacological Sciences (TiPS), The Biochemical Journal, Acta Pharmacologica Sinica and ACS Pharmacology and Translational Science. His research achievements include the discovery of a non-peptidic glucagon-like peptide-1 receptor agonist Boc5, determination of the 3-D structures of human glucagon receptor, glucagon-like peptide-1 receptor and parathyroid hormone receptor-1, elucidation of the insulinotrophic effect of insulin-like peptide 5 and identification of the link of GPR160 (an orphan GPCR) and prostate cancer.‍‍‍‍

‍‍Mr. Wu is currently the Representative of the 13th National People’s Congress of Jiangsu Province, as well as executive member of China Society for Drug Regulation, Vice Chairman of China News of Drug Information Association; Vice Chairman of Chinese Pharmaceutical Enterprises Association; and Vice Chairman of China Nonprescription Medicines Association.  ‍‍

‍‍Mr. Wu graduated from Nanjing University of Science and Technology majoring in international commerce in 1996 and obtained a master degree in business administration from Saint Joseph’s University in 2005.‍‍‍‍

‍‍Zhao Wei-Li, M.D., PhD, Professor of Hematology, Associate Director of Shanghai Institute of Hematology and Associate Chief Physician of Department of Hematology, Shanghai Ruijin Hospital. She is the doctoral supervisor of both Shanghai Jiao Tong University and University Paris VII, foreign member of American Society of Hematology, Vice Secretary General of Chinese Society of Experimental Hematology, Member of Chinese Association of Hematology, and member of the editorial committee of Pathobiology, Biomarker Research, Chinese Journal of Hematology, Chinese Journal of Leukemia & Lymphoma, and Clinical Hematology Journal. She mainly focuses on the clinical and basic research of hematological malignancies, especially the molecular markers and targeted therapy of leukemia and lymphoma. She innovatively proposed the molecular pathways of apoptosis, angiogenesis and cell differentiation involved in lymphoma progression and the availability of targeted therapy for its treatment. She has been awarded Outstanding Achievement Award of Scientific Research from National Ministry of Education and HUA XIA Award of Medicine and Technology from National Ministry of Science and Technology for her research progress and is now leading projects granted by National High Technology Research and Development Program of China, by National Natural Science Foundation of China and several other events on provincial level. She has been honored New Century Excellent Talents in University by State Ministry of Education, Rising-Star by Shanghai Committee of Science and Technology, Shu Guang Scholar by Shanghai Municipal Educational Committee. She has published over 60 articles including those on leading hematology journals like Blood and Leukemia with total impact factors over 200.‍‍